Antibody-Based Mapping of Pseudouridine on mRNA and HIV-1 RNA

Study Background and Research Question

Messenger RNA (mRNA) molecules in eukaryotic cells undergo a spectrum of chemical modifications—collectively termed epitranscriptomic changes—that deeply influence their fate, including translation efficiency, stability, and immune recognition. Among these, pseudouridine (Ψ) stands out as the most abundant noncanonical ribonucleoside in noncoding RNAs, yet its precise distribution and functional impact on mRNA remain incompletely mapped. Previous research has established that Ψ can dampen innate immune responses to exogenous RNA and enhance mRNA stability, properties leveraged in the design of mRNA vaccines. However, it has remained unclear which enzymes install Ψ on mRNA, and particularly how this modification manifests on viral transcripts such as those from HIV-1. The reference study sought to address these gaps by developing a sensitive mapping technique and dissecting the enzymatic origins of Ψ in both cellular and viral contexts.

Key Innovation from the Reference Study

The central innovation of this study is the development and validation of photo-crosslinking-assisted pseudouridine sequencing (PA-Ψ-seq), an antibody-based method that enables transcriptome-wide mapping of Ψ residues with high specificity and spatial resolution. Unlike previous chemical approaches, PA-Ψ-seq capitalizes on a Ψ-specific antibody and photo-crosslinking to enrich and identify modified sites, offering a scalable and less labor-intensive workflow. This approach was applied not only to cellular RNAs but also to viral RNAs, including HIV-1 genomic and messenger RNA, thus expanding the toolkit for investigating the functional landscape of RNA modifications in both host and pathogen.

Methods and Experimental Design Insights

PA-Ψ-seq involves incubating RNA samples with a high-affinity anti-Ψ antibody, followed by UV-induced photo-crosslinking to covalently link the antibody to Ψ-modified nucleotides. After immunoprecipitation and stringent washes to remove nonspecific binding, the crosslinked RNA is isolated, reverse transcribed, and subjected to high-throughput sequencing. The resulting data pinpoint Ψ sites at nucleotide-level resolution. To dissect the enzymatic origin of Ψ, the authors generated 293T cell lines with individual knockouts of three known human pseudouridine synthase (PUS) enzymes: PUS1, PUS7, and TRUB1 (PUS4). Comparative mapping in wild-type and knockout lines enabled attribution of specific Ψ sites to these enzymes.

Protocol Parameters

• Antibody incubation: Use a Ψ-specific monoclonal antibody at optimized concentration (typically 1–2 μg per 100 μg total RNA) for overnight binding at 4°C to maximize specificity and yield.
• Photo-crosslinking: Expose samples to 254 nm UV light for 15–20 minutes on ice to induce crosslinking between antibody and modified nucleotides.
• Immunoprecipitation: Employ protein A/G magnetic beads and perform washes under high-salt conditions (e.g., 500 mM NaCl) to reduce background.
• RNA purification and sequencing: Following reversal of crosslinks, purify RNA by phenol-chloroform extraction and proceed to reverse transcription and standard RNA-seq library preparation.
• Knockout validation: Confirm gene edits in PUS1, PUS7, and TRUB1 by Western blotting and Sanger sequencing before downstream mapping.

These parameters reflect the reference protocol. For adaptation to other cell types or viral systems, preliminary optimization of antibody binding and crosslinking may be required.

Core Findings and Why They Matter

Mapping with PA-Ψ-seq confirmed that Ψ is present at modest levels (∼0.1% of uridines) on human mRNA, consistent with prior estimates. Knockout of PUS1, PUS7, or TRUB1 revealed that each enzyme contributes to distinct but limited sets of Ψ sites on cellular mRNA. However, the overall abundance of Ψ on mRNA was not significantly reduced in any single knockout, nor did the combined knockouts reduce Ψ levels below those observed in wild-type cells. This suggests that additional, as yet unidentified, PUS enzymes or alternative mechanisms are responsible for the majority of Ψ installation on mRNA (reference study).

Strikingly, the authors found that the Ψ landscape on HIV-1 transcripts was unaffected by disruption of PUS1, PUS7, or TRUB1, implying that viral mRNAs may use a distinct set of host enzymes or pathways for Ψ modification. This observation is particularly significant given that pseudouridine incorporation into viral mRNA can dampen host immune detection, potentially enhancing viral replication and immune evasion. These data reveal a previously unappreciated complexity in the regulation of RNA modifications and underscore the need to identify the full repertoire of PUS enzymes active on mRNA and viral RNA.

Functionally, the presence of Ψ on exogenous or synthetic mRNA is known to suppress innate immune activation and improve transcript stability—a principle exploited in the design of mRNA vaccines such as those against COVID-19. The identification of Ψ on HIV-1 RNA raises the possibility that similar mechanisms are at play in viral immune evasion, though direct functional studies remain to be performed.

Comparison with Existing Internal Articles

Several internal resources, such as "HyperScribe™ T7 High Yield RNA Synthesis Kit: Precision In Vitro Transcription for Advanced RNA Research" and "HyperScribe™ T7 High Yield RNA Synthesis Kit: High-Yield, Versatile RNA Synthesis", emphasize the importance of robust in vitro transcription platforms for generating functionally modified RNA, including capped, biotinylated, or pseudouridine-containing transcripts. These articles outline how high-yield in vitro transcription using T7 RNA polymerase facilitates application-driven workflows in RNA therapeutics, structure-function studies, and RNA interference experiments. The internal articles primarily focus on the technical and workflow benefits of using advanced RNA synthesis kits for producing research-grade RNA, while the reference study provides mechanistic insights into the endogenous and viral installation of pseudouridine, connecting RNA modification mapping with functional genomics and immunology. Integrating robust synthesis tools, such as those discussed in internal resources, with advanced mapping techniques like PA-Ψ-seq, enables a comprehensive approach to both the generation and characterization of modified RNAs for translational research.

Limitations and Transferability

The PA-Ψ-seq method, while impactful, relies on the specificity and sensitivity of the anti-Ψ antibody, which may vary between lots or suppliers. Quantitative interpretation of Ψ stoichiometry at individual sites is also limited, as the method is primarily qualitative and enrichment-based. Additionally, the knockout strategy interrogated only three PUS enzymes; functional redundancy or compensation by other family members cannot be ruled out. The study was performed in 293T cells and HIV-1, and while the approach is broadly applicable, transferability to other cell types or viruses should be validated empirically. The identity of the major PUS enzyme(s) responsible for the bulk of mRNA pseudouridylation remains an open question, limiting immediate translational insight but offering a fertile area for future research.

Research Support Resources

Researchers interested in synthesizing and characterizing modified RNAs, including pseudouridine- or N1-methylpseudouridine-containing transcripts for capped RNA synthesis, biotinylated RNA synthesis, or RNA vaccine research, can leverage advanced in vitro transcription systems. The HyperScribe™ T7 High Yield RNA Synthesis Kit (SKU K1047) from APExBIO is a validated platform supporting T7 RNA polymerase transcription of high-yield, diverse RNA types, including those required for functional and mechanistic studies like those described in the reference paper. Integrating such synthesis tools with antibody-based mapping techniques or RNA interference experiments can streamline workflows for probing the role of RNA modifications in gene regulation and immunity.